Abstract: An isolated antigen-binding protein, having one or more of the following properties: 1) capable of binding to human and monkey-derived GITR proteins at a KD value of 7×10?12 or below, wherein the KD value is measured by BLI method; 2) capable of stimulating immune cell proliferation; 3) capable of stimulating immune cells to secrete IFN-?, wherein the secretion is measured in T cell viability assay; 4) capable of inhibiting tumor growth and/or tumor cell proliferation; 5) capable of activating GITR signaling pathway; 6) capable of inhibiting the binding of GITR to GITRL.

Abstract: An antibody may be capable of specifically binding CD137 or an antigen binding fragment thereof, wherein the light chain variable region and the heavy chain variable region have one or more mutations. The antibody or antigen binding fragment thereof may be used in preparing a drug. The antibody or an antigen binding fragment thereof may specifically bind CD137, and may include a light chain variable region VL and a heavy chain variable region VH, wherein compared to a sequence as shown in SEQ ID NO: 103, the VL comprises one or more VL amino acid mutations, and the VL amino acid mutation occurs at one or more positions: V3, A10, K44, D71, and/or V77.

Abstract: An isolated antigen-binding protein, having one or more of the following properties: 1) capable of binding to human and monkey-derived GITR proteins at a KD value of 7×10?12 or below, wherein the KD value is measured by BLI method; 2) capable of stimulating immune cell proliferation; 3) capable of stimulating immune cells to secrete IFN-?, wherein the secretion is measured in T cell viability assay; 4) capable of inhibiting tumor growth and/or tumor cell proliferation; 5) capable of activating GITR signaling pathway; 6) capable of inhibiting the binding of GITR to GITRL.

Abstract: Proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.

Abstract: The present disclosure provides proteinaceous complexes, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous complexes, methods for producing the proteinaceous complexes, and uses thereof.

Abstract: An antibody may be capable of specifically binding CD137 or an antigen binding fragment thereof, wherein the light chain variable region and the heavy chain variable region have one or more mutations. The antibody or antigen binding fragment thereof may be used in preparing a drug. The antibody or an antigen binding fragment thereof may specifically bind CD137, and may include a light chain variable region VL and a heavy chain variable region VH, wherein compared to a sequence as shown in SEQ ID NO: 103, the VL comprises one or more VL amino acid mutations, and the VL amino acid mutation occurs at one or more positions: V3, A10, K44, D71, and/or V77.

Abstract: A directional coupler and a method for manufacturing the same are disclosed. According to an embodiment, the directional coupler comprises a first transmission line configured to receive an input signal. The directional coupler further comprises a second transmission line that can be coupled to the first transmission line by electromagnetic coupling to output a coupled signal. The first transmission line is further configured to act as a quarter-wave impedance transformer. A radio transmitter comprising the directional coupler and a radio device comprising the radio transmitter are also disclosed.

Abstract: Disclosed are a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof. a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof.

Abstract: A directional coupler and a method for manufacturing the same are disclosed. According to an embodiment, the directional coupler comprises a first transmission line configured to receive an input signal. The directional coupler further comprises a second transmission line that can be coupled to the first transmission line by electromagnetic coupling to output a coupled signal. The first transmission line is further configured to act as a quarter-wave impedance transformer. A radio transmitter comprising the directional coupler and a radio device comprising the radio transmitter are also disclosed.

Abstract: The present application provides an anti-OX40 human antibody. In particular, a human antibody specifically binding to OX40 is obtained with yeast display screening, and the affinity of the antibody is improved with affinity maturation. The present application also provides a use of the antibody for the prevention or treatment of tumors.

Abstract: The present disclosure provides proteinaceous complexes, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous complexes, methods for producing the proteinaceous complexes, and uses thereof.

Abstract: The present disclosure provides proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.

Abstract: The present application provides an anti-OX40 human antibody. In particular, a human antibody specifically binding to OX40 is obtained with yeast display screening, and the affinity of the antibody is improved with affinity maturation. The present application also provides a use of the antibody for the prevention or treatment of tumors.

Abstract: Disclosed are a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof. a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof.